Details of Disease

Disease Name

Kidney neoplasm

neoplasm of the kidney; kidney neoplasm; renal tumors; kidney tumor; renal tumor; tumour of the kidney; renal neoplasm; kidney tumour; tumor of the kidney; renal tumour; tumour of kidney; tumor of kidney; kidney neoplasm (disease); neoplasm of kidney; renal tumours

Definition

A benign or malignant neoplasm affecting the kidney. Representative examples of benign renal neoplasms include fibroma, lipoma, oncocytoma, and juxtaglomerular cell tumor. Representative examples of malignant renal neoplasms include renal cell carcinoma, renal pelvis carcinoma, Wilms tumor, rhabdoid tumor, sarcoma, and lymphoma.

Disease Hierarchy

DISTBY9Z: Tumour

DIS1VI2T: Urinary system neoplasm

DISXWP4P: Nephropathy

DISBNZTN: Kidney neoplasm

Disease Identifiers

MONDO ID

MONDO_0021163

MESH ID

D007680

UMLS CUI

C0022665

MedGen ID

5967

HPO ID

HP:0009726

SNOMED CT ID

126880001

General Information of Disease (ID: DISBNZTN)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[1]
Etoposide	DMNH3PG	Approved	Small molecular drug	[2]
Ifosfamide	DMCT3I8	Approved	Small molecular drug	[3]
Irinotecan	DMP6SC2	Approved	Small molecular drug	[4]
Temozolomide	DMKECZD	Approved	Small molecular drug	[5]
Vincristine	DMINOX3	Approved	Small molecular drug	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRAF	TT0EOB8	Limited	Genetic Variation	[7]
MAGEA2	TTOZT28	Limited	Biomarker	[8]
OGG1	TTRU01G	Limited	Altered Expression	[9]
RCVRN	TTDQTEY	Limited	Biomarker	[10]
SLC5A5	TTW7HI9	Limited	Therapeutic	[11]
VHL	TTEMWSD	Disputed	Altered Expression	[12]
CHEK2	TT9ABMF	moderate	ModifyingMutation	[13]
SORD	TTLSRBZ	moderate	Biomarker	[14]
ATP7B	TTOPO51	Strong	Biomarker	[15]
AURKA	TTPS3C0	Strong	Biomarker	[16]
AXL	TTZPY6J	Strong	Biomarker	[17]
BAP1	TT47RXJ	Strong	Biomarker	[18]
CCND1	TTFCJ7S	Strong	Biomarker	[19]
CDKN1B	TTLGFVW	Strong	Biomarker	[19]
COL6A3	TT5WCAH	Strong	Altered Expression	[20]
CRHR2	TTIY658	Strong	Altered Expression	[21]
CSNK1E	TTA8PLI	Strong	Altered Expression	[22]
CTH	TTLQUZS	Strong	Biomarker	[23]
ENPEP	TT9PBIL	Strong	Biomarker	[24]
FOLH1	TT9G4N0	Strong	Altered Expression	[25]
GABRE	TTBY4OD	Strong	Altered Expression	[26]
HAMP	TTRV5YJ	Strong	Biomarker	[27]
HPGDS	TTCYE56	Strong	Biomarker	[27]
IL32	TTD4G7L	Strong	Biomarker	[28]
MAGEA3	TTWSKHD	Strong	Biomarker	[29]
MAPK3	TT1MG9E	Strong	Biomarker	[30]
POLB	TTA0XPV	Strong	Genetic Variation	[31]
POLR2G	TTD4YFP	Strong	Biomarker	[32]
RAF1	TTAN5W2	Strong	Biomarker	[30]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[28]
TNFSF10	TTA5MS9	Strong	Therapeutic	[33]
TPH1	TTZSJHV	Strong	Biomarker	[27]
TPT1	TT3PTB6	Strong	Biomarker	[27]
UBE2T	TT0A1R8	Strong	Biomarker	[27]
ABCB1	TT3OT40	Definitive	Biomarker	[34]
EIF4EBP1	TTKGEBL	Definitive	Biomarker	[30]
IL2	TTF89GD	Definitive	Therapeutic	[35]
MAPK1	TT4TQBX	Definitive	Biomarker	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 38 DTT(s)

This Disease Is Related to 4 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC22A13	DT38SZL	Limited	Biomarker	[36]
SLC25A3	DTCRIWV	Limited	Altered Expression	[37]
SLC13A2	DTUO05P	Strong	Biomarker	[38]
SLC25A5	DTL1TRY	Strong	Altered Expression	[39]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP1A1	DE6OQ3W	Strong	Biomarker	[40]
GSTT1	DE3PKUG	Strong	Biomarker	[41]
KYAT1	DES9MCU	Strong	Biomarker	[41]
------------------------------------------------------------------------------------

This Disease Is Related to 68 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CDC73	OT6JASZ1	Limited	Genetic Variation	[42]
EWSR1	OT7SRHV3	Limited	Genetic Variation	[43]
HAVCR1	OT184CRZ	Limited	Biomarker	[44]
JADE1	OTBPJIRI	Limited	Biomarker	[45]
NIBAN1	OTYOLI12	Limited	Altered Expression	[46]
NME4	OT2JTT42	Limited	Altered Expression	[47]
PAX2	OTKP1N8F	Limited	Biomarker	[48]
PAX8	OTRPD9MI	Limited	Biomarker	[49]
PTPRU	OTHDO0QG	Limited	Altered Expression	[37]
TFEB	OTJUJJQY	Limited	Altered Expression	[50]
TSC1	OTFF4YZ7	Limited	Biomarker	[51]
SAG	OTDNS3ZQ	Disputed	Altered Expression	[52]
SARDH	OTQ49Q27	moderate	Biomarker	[14]
SCUBE1	OT4JY1UY	moderate	Biomarker	[53]
SDS	OT5WTJ2M	moderate	Biomarker	[14]
AKT1S1	OT4JHN4Y	Strong	Altered Expression	[54]
AMFR	OTQRX7LC	Strong	Biomarker	[55]
APH1A	OT97F1TU	Strong	Biomarker	[56]
ASPSCR1	OTXTOD10	Strong	Genetic Variation	[57]
BCCIP	OTFFKG79	Strong	Altered Expression	[58]
CACYBP	OTJMZD2T	Strong	Biomarker	[59]
CALB1	OTM7IXDG	Strong	Genetic Variation	[60]
CDH16	OTR0GE9G	Strong	Altered Expression	[61]
CHMP1A	OTVQ5UWX	Strong	Altered Expression	[62]
CLDN8	OT7IIWXG	Strong	Biomarker	[48]
CPQ	OTTNZNLD	Strong	Biomarker	[63]
CREB3L1	OT2JHIHM	Strong	Genetic Variation	[43]
DLG2	OTQ3BD8U	Strong	Altered Expression	[64]
DNM3	OTDMUGCR	Strong	Biomarker	[27]
ESCO2	OTJEMAQU	Strong	Biomarker	[27]
ESM1	OT331Y8V	Strong	Altered Expression	[65]
FIGNL1	OTKII63K	Strong	Biomarker	[27]
FNIP1	OTB1CC41	Strong	Genetic Variation	[66]
FOXP4	OTHCGIEZ	Strong	Biomarker	[67]
FZD5	OTXFFY56	Strong	Altered Expression	[68]
GDF9	OTNTVKVU	Strong	Altered Expression	[69]
GIPC1	OTXLVCPJ	Strong	Altered Expression	[70]
GIPC2	OT68YFO1	Strong	Altered Expression	[71]
HILPDA	OTEID3ZM	Strong	Altered Expression	[72]
JAML	OTOJHNEV	Strong	Biomarker	[73]
KAT8	OT5LPQTR	Strong	Altered Expression	[74]
LRIG1	OTY5HZN5	Strong	Altered Expression	[75]
LRPAP1	OT6DVD2Q	Strong	Altered Expression	[76]
MAX	OTKZ0YKM	Strong	Biomarker	[77]
MITF	OT6XJCZH	Strong	Genetic Variation	[78]
MPST	OTCDPH5D	Strong	Biomarker	[23]
MR1	OTZU3XX7	Strong	Biomarker	[79]
NDRG1	OTVO66BO	Strong	Biomarker	[80]
NMU	OTW9X7BQ	Strong	Altered Expression	[81]
OSGIN1	OT9KIVZW	Strong	Altered Expression	[82]
PLCG2	OTGVC9MY	Strong	Biomarker	[83]
RAB27B	OTPF9D0K	Strong	Biomarker	[83]
RANBP1	OTQE226K	Strong	Biomarker	[27]
RASSF5	OT6Q41I2	Strong	Biomarker	[84]
REXO1	OTZT6RAW	Strong	Altered Expression	[85]
RHOU	OTERIAD4	Strong	Altered Expression	[86]
SDHB	OTRE1M1T	Strong	Biomarker	[87]
SFPQ	OTLCIAPJ	Strong	Biomarker	[56]
SIX2	OTYOVGSC	Strong	Biomarker	[88]
SPAG4	OTVXS2SM	Strong	Biomarker	[89]
TBP	OT6C0S52	Strong	Altered Expression	[90]
TESC	OTI8C76M	Strong	Altered Expression	[91]
TFE3	OTM99ZWH	Strong	Genetic Variation	[92]
TMEM127	OTYHUXC1	Strong	Biomarker	[93]
BCOR	OTG013AX	Definitive	Biomarker	[94]
HLTF	OTRX2OSF	Definitive	Biomarker	[95]
PGP	OT6QQ7OR	Definitive	Genetic Variation	[96]
TSC2	OT47LWI9	Definitive	Biomarker	[51]
------------------------------------------------------------------------------------


⏷ Show the Full List of 68 DOT(s)

References

1	Doxorubicin FDA Label
2	Etoposide FDA Label
3	Ifosfamide FDA Label
4	Irinotecan FDA Label
5	Temozolomide FDA Label
6	Vincristine FDA Label
7	BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors.Hum Pathol. 2017 Feb;60:32-36. doi: 10.1016/j.humpath.2016.09.025. Epub 2016 Oct 18.
8	On-clamp versus off-clamp partial nephrectomy: Propensity score-matched comparison of long-term functional outcomes.Int J Urol. 2019 Oct;26(10):985-991. doi: 10.1111/iju.14079. Epub 2019 Jul 24.
9	Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells.Carcinogenesis. 2010 Nov;31(11):2022-30. doi: 10.1093/carcin/bgq189. Epub 2010 Sep 13.
10	The cancer-retina antigen recoverin as a potential biomarker for renal tumors.Tumour Biol. 2016 Jul;37(7):9899-907. doi: 10.1007/s13277-016-4885-5. Epub 2016 Jan 26.
11	The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.Cancer Gene Ther. 2003 Jan;10(1):14-22. doi: 10.1038/sj.cgt.7700525.
12	Transcriptomic expression levels of the VHL, TIMP-3, and RASSF1A genes in renal tumors.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9313-9320. doi: 10.26355/eurrev_201911_19424.
13	Cellular distribution of cell cycle-related molecules in the renal tubules of rats treated with renal carcinogens for 28 days: relationship between cell cycle aberration and carcinogenesis.Arch Toxicol. 2012 Sep;86(9):1453-64. doi: 10.1007/s00204-012-0829-z. Epub 2012 Mar 13.
14	Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum.J Clin Endocrinol Metab. 2015 Oct;100(10):E1386-93. doi: 10.1210/jc.2015-2689. Epub 2015 Aug 10.
15	Role of Atp7b gene in spontaneous and N-diethylnitrosamine-induced carcinogenesis in a new congenic strain, WKAH.C-Atp7b rats.Jpn J Cancer Res. 2001 Aug;92(8):841-7. doi: 10.1111/j.1349-7006.2001.tb01170.x.
16	Expression of selected Aurora A kinase substrates in solely estrogen-induced ectopic uterine stem cell tumors in the Syrian hamster kidney.Adv Exp Med Biol. 2008;617:411-8. doi: 10.1007/978-0-387-69080-3_39.
17	Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden.PLoS One. 2014 Dec 31;9(12):e115916. doi: 10.1371/journal.pone.0115916. eCollection 2014.
18	Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells.Mol Cell Proteomics. 2019 Jul;18(7):1320-1329. doi: 10.1074/mcp.RA119.001457. Epub 2019 Apr 16.
19	cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci. 2011 Aug;122(2):361-71. doi: 10.1093/toxsci/kfr118. Epub 2011 Jun 20.
20	Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.BMC Genomics. 2016 Dec 28;17(Suppl 14):1011. doi: 10.1186/s12864-016-3351-5.
21	Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.World J Urol. 2009 Dec;27(6):825-30. doi: 10.1007/s00345-009-0417-x.
22	Altered expression of the clock gene machinery in kidney cancer patients.Biomed Pharmacother. 2012 Apr;66(3):175-9. doi: 10.1016/j.biopha.2011.11.007. Epub 2011 Dec 21.
23	Endogenous H(2)S producing enzymes are involved in apoptosis induction in clear cell renal cell carcinoma.BMC Cancer. 2018 May 24;18(1):591. doi: 10.1186/s12885-018-4508-1.
24	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.PLoS One. 2017 Aug 15;12(8):e0181711. doi: 10.1371/journal.pone.0181711. eCollection 2017.
25	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.
26	Regulatory feedback loop between T3 and microRNAs in renal cancer.Mol Cell Endocrinol. 2014 Mar 25;384(1-2):61-70. doi: 10.1016/j.mce.2014.01.006. Epub 2014 Jan 17.
27	Investigation of the early-response genes in chemical-induced renal carcinogenicity for the prediction of chemical carcinogenicity in rats.J Toxicol Sci. 2017;42(2):175-181. doi: 10.2131/jts.42.175.
28	Expression of acidosis-dependent genes in human cancer nests.Mol Clin Oncol. 2014 Nov;2(6):1160-1166. doi: 10.3892/mco.2014.344. Epub 2014 Jul 11.
29	Lymphatic Drainage from Renal Tumors InVivo: A Prospective Sentinel Node Study Using SPECT/CT Imaging.J Urol. 2018 Jun;199(6):1426-1432. doi: 10.1016/j.juro.2017.11.112. Epub 2017 Dec 6.
30	ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.Toxicol Sci. 2011 Nov;124(1):75-87. doi: 10.1093/toxsci/kfr203. Epub 2011 Aug 2.
31	Lack of mutations in DNA polymerase beta of estradiol-induced hamster kidney tumors: sequence of hamster DNA polymerase beta cDNA.Int J Oncol. 1999 Aug;15(2):353-9. doi: 10.3892/ijo.15.2.353.
32	Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 2003 Aug 15;22(16):4249-59.
33	Gene therapy with TRAIL against renal cell carcinoma.Mol Cancer Ther. 2006 Sep;5(9):2165-71. doi: 10.1158/1535-7163.MCT-05-0522.
34	MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.Mol Biol Rep. 2012 Jul;39(7):7237-49. doi: 10.1007/s11033-012-1554-7. Epub 2012 Feb 4.
35	High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.Cancer Biother Radiopharm. 2009 Apr;24(2):181-3. doi: 10.1089/cbr.2008.0564.
36	The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis.Oncogene. 2015 Mar 26;34(13):1718-28. doi: 10.1038/onc.2014.93. Epub 2014 Apr 28.
37	17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.Anticancer Res. 2000 Jan-Feb;20(1A):11-9.
38	Expression of sodium-dependent dicarboxylate transporter 1 (NaDC1/SLC13A2) in normal and neoplastic human kidney.Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F427-F435. doi: 10.1152/ajprenal.00559.2016. Epub 2016 Dec 7.
39	Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines.Mol Carcinog. 1996 Jul;16(3):165-72. doi: 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G.
40	Somatic mutations in stilbene estrogen-induced Syrian hamster kidney tumors identified by DNA fingerprinting.J Carcinog. 2004 Mar 5;3(1):4. doi: 10.1186/1477-3163-3-4.
41	Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants.Cancer Res. 2010 Aug 15;70(16):6527-36. doi: 10.1158/0008-5472.CAN-09-4167. Epub 2010 Jul 27.
42	Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene.Oncogene. 2007 May 17;26(23):3440-9. doi: 10.1038/sj.onc.1210131. Epub 2006 Nov 27.
43	Primary low-grade fibromyxoid sarcoma of the kidney in a child with the alternative EWSR1-CREB3L1 gene fusion.Pediatr Dev Pathol. 2014 Jul-Aug;17(4):321-6. doi: 10.2350/14-05-1487-CR.1. Epub 2014 Jun 4.
44	A Phage Display-Identified Peptide Selectively Binds to Kidney Injury Molecule-1 (KIM-1) and Detects KIM-1-Overexpressing Tumors in vivo.Cancer Res Treat. 2019 Jul;51(3):861-875. doi: 10.4143/crt.2018.214. Epub 2018 Oct 1.
45	Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and -catenin regulation.Prog Biophys Mol Biol. 2019 Aug;145:65-77. doi: 10.1016/j.pbiomolbio.2018.12.005. Epub 2018 Dec 7.
46	Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis.Oncogene. 2004 Apr 22;23(19):3495-500. doi: 10.1038/sj.onc.1207468.
47	Overexpression of nm23-H4 RNA in colorectal and renal tumours.Anticancer Res. 2001 Jul-Aug;21(4A):2821-5.
48	Immunohistochemical diagnosis of renal neoplasms.Arch Pathol Lab Med. 2011 Jan;135(1):92-109. doi: 10.5858/2010-0478-RAR.1.
49	Immunohistochemical Profile of 20 Feline Renal Cell Carcinomas.J Comp Pathol. 2017 Aug-Oct;157(2-3):115-125. doi: 10.1016/j.jcpa.2017.06.004. Epub 2017 Jul 26.
50	TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.Am J Surg Pathol. 2019 Nov;43(11):1445-1461. doi: 10.1097/PAS.0000000000001307.
51	mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.Cell Death Differ. 2019 Oct;26(10):2015-2028. doi: 10.1038/s41418-019-0274-0. Epub 2019 Feb 13.
52	Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.Biochimie. 2019 Feb;157:26-37. doi: 10.1016/j.biochi.2018.10.019. Epub 2018 Oct 30.
53	SCUBE1: a promising biomarker in renal cell cancer.Int Braz J Urol. 2017 Jul-Aug;43(4):638-643. doi: 10.1590/S1677-5538.IBJU.2016.0316.
54	Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.PLoS One. 2011;6(8):e23919. doi: 10.1371/journal.pone.0023919. Epub 2011 Aug 23.
55	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.Medicine (Baltimore). 2015 Nov;94(46):e2117. doi: 10.1097/MD.0000000000002117.
56	A case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with melanotic features.Hum Pathol. 2015 Mar;46(3):476-81. doi: 10.1016/j.humpath.2014.11.013. Epub 2014 Dec 9.
57	Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.Am J Pathol. 2001 Jul;159(1):179-92. doi: 10.1016/S0002-9440(10)61684-7.
58	Genomic structure of the human BCCIP gene and its expression in cancer.Gene. 2003 Jan 2;302(1-2):139-46. doi: 10.1016/s0378-1119(02)01098-3.
59	Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma.Biochem Biophys Res Commun. 2007 May 18;356(4):864-71. doi: 10.1016/j.bbrc.2007.03.080. Epub 2007 Mar 26.
60	Suppression of calbindin D28K in estrogen-induced hamster renal tumors.J Steroid Biochem Mol Biol. 2004 Dec;92(5):391-8. doi: 10.1016/j.jsbmb.2004.07.009. Epub 2004 Dec 19.
61	Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma.Am J Clin Pathol. 2006 Jul;126(1):79-85. doi: 10.1309/JFE2-B57Y-QFPW-PL10.
62	Chmp1A acts as a tumor suppressor gene that inhibits proliferation of renal cell carcinoma.Cancer Lett. 2012 Jun 28;319(2):190-196. doi: 10.1016/j.canlet.2012.01.010. Epub 2012 Jan 17.
63	Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):316-323. doi: 10.1097/PAI.0000000000000435.
64	Differential expression of a new isoform of DLG2 in renal oncocytoma.BMC Cancer. 2006 Apr 26;6:106. doi: 10.1186/1471-2407-6-106.
65	Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.Exp Cell Res. 2007 Apr 15;313(7):1285-94. doi: 10.1016/j.yexcr.2007.01.021. Epub 2007 Feb 6.
66	Identification and characterization of a novel folliculin-interacting protein FNIP2.Gene. 2008 May 31;415(1-2):60-7. doi: 10.1016/j.gene.2008.02.022. Epub 2008 Mar 4.
67	FoxP4, a novel forkhead transcription factor.Biochim Biophys Acta. 2003 Jun 19;1627(2-3):147-52. doi: 10.1016/s0167-4781(03)00074-5.
68	Alteration of frizzled expression in renal cell carcinoma.Tumour Biol. 2004 Jul-Aug;25(4):161-71. doi: 10.1159/000081098.
69	Loss of expression of growth differentiation factor-9 (GDF9) in human kidney cancer and regulation of growth and migration of kidney cancer cells by GDF9.Anticancer Res. 2012 Oct;32(10):4375-83.
70	Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors.Int J Mol Med. 2002 May;9(5):509-13.
71	Molecular cloning and characterization of human GIPC2, a novel gene homologous to human GIPC1 and Xenopus Kermit.Int J Oncol. 2002 Mar;20(3):571-6.
72	Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells.BMC Cancer. 2005 Jan 10;5:3. doi: 10.1186/1471-2407-5-3.
73	Chart for renal tumor microwave ablation from human study.Diagn Interv Imaging. 2018 Oct;99(10):609-614. doi: 10.1016/j.diii.2018.05.005. Epub 2018 Jun 15.
74	Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma.J Exp Clin Cancer Res. 2013 Feb 9;32(1):8. doi: 10.1186/1756-9966-32-8.
75	Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement.Hum Mol Genet. 2004 May 1;13(9):983-90. doi: 10.1093/hmg/ddh111. Epub 2004 Mar 11.
76	Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.Anticancer Res. 1991 Jul-Aug;11(4):1657-62.
77	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562.
78	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.Mod Pathol. 2018 Jan;31(1):179-197. doi: 10.1038/modpathol.2017.99. Epub 2017 Aug 25.
79	Expression and clinical value of the soluble major histocompatibility complex class I-related chain A molecule in the serum of patients with renal tumors.Genet Mol Res. 2015 Jun 29;14(2):7233-40. doi: 10.4238/2015.June.29.16.
80	Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers.BMC Genet. 2004 Sep 2;5:27. doi: 10.1186/1471-2156-5-27.
81	Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.Mol Cancer. 2011 Jul 26;10:89. doi: 10.1186/1476-4598-10-89.
82	The role of 5' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma.Oncogene. 2007 Feb 22;26(8):1155-65. doi: 10.1038/sj.onc.1209896. Epub 2006 Aug 21.
83	Gene expression and protein array studies of folliculin-regulated pathways.Anticancer Res. 2012 Nov;32(11):4663-70.
84	Ras regulates SCF(-TrCP) protein activity and specificity via its effector protein NORE1A.J Biol Chem. 2014 Nov 7;289(45):31102-10. doi: 10.1074/jbc.M114.594283. Epub 2014 Sep 12.
85	Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.Carcinogenesis. 2006 Mar;27(3):499-507. doi: 10.1093/carcin/bgi299. Epub 2005 Dec 12.
86	Expression of WRCH1 in human cancer and down-regulation of WRCH1 by beta-estradiol in MCF-7 cells.Int J Oncol. 2002 Apr;20(4):777-83.
87	A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling.Am J Surg Pathol. 2015 Jun;39(6):858-63. doi: 10.1097/PAS.0000000000000403.
88	The pluripotent renal stem cell regulator SIX2 is activated in renal neoplasms and influences cellular proliferation and migration.Hum Pathol. 2013 Mar;44(3):336-45. doi: 10.1016/j.humpath.2012.05.021. Epub 2012 Sep 17.
89	Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.Mol Carcinog. 2014 Dec;53(12):970-8. doi: 10.1002/mc.22065. Epub 2013 Jul 2.
90	Reference genes for gene expression analysis by real-time reverse transcription polymerase chain reaction of renal cell carcinoma.Diagn Mol Pathol. 2011 Dec;20(4):212-7. doi: 10.1097/PDM.0b013e318212e0a9.
91	Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations.Cancer Biol Ther. 2004 Dec;3(12):1313-21. doi: 10.4161/cbt.3.12.1459. Epub 2004 Dec 9.
92	Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.Am J Transl Res. 2019 Jan 15;11(1):327-339. eCollection 2019.
93	Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).Endocr Pathol. 2017 Sep;28(3):253-268. doi: 10.1007/s12022-017-9489-0.
94	Clear Cell Sarcoma of the Kidney.Arch Pathol Lab Med. 2020 Jan;144(1):119-123. doi: 10.5858/arpa.2018-0353-RS. Epub 2019 Mar 27.
95	The helicase-like transcription factor and its implication in cancer progression.Cell Mol Life Sci. 2008 Feb;65(4):591-604. doi: 10.1007/s00018-007-7392-4.
96	Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.J Am Soc Nephrol. 2002 Jul;13(7):1847-54. doi: 10.1097/01.asn.0000019412.87412.bc.